Astra Zeneca

In 2023, AstraZeneca reported total greenhouse gas emissions of approximately 6,000,000 kg CO2e across all scopes. This includes about 180,898,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and approximately 19,940,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. The company also disclosed significant Scope 3 emissions, amounting to about 5,917,160,000 kg CO2e, which cover all other indirect emissions in the value chain. AstraZeneca has set ambitious climate commitments, aiming for a 98% reduction in absolute Scope 1 and 2 GHG emissions by 2026, using 2015 as the baseline year. Additionally, the company targets a 50% reduction in absolute Scope 3 emissions by 2030, with specific goals to cut emissions from various categories, including an 80% reduction from fuel and energy-related activities and a 95% reduction from the use of sold products, all from a 2019 baseline. The company is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2045, aligning with the Science Based Targets initiative (SBTi) to ensure its targets are consistent with the global goal of limiting temperature rise to 1.5°C. AstraZeneca also aims for 95% of its suppliers by spend to have science-based targets by 2025, further enhancing its sustainability efforts.